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Abstract. The regulation of gene transcription is not sim-
ply dependent on the presence or absence of DNA-bind-
ing transcription factors that turn genes on or off, but also
involves processes determining the ability of transcrip-
tion factors to gain access to and bind their target DNA.
Methylation of DNA cytosine bases leads to the inacces-
sibility of DNA regulatory elements to their transcription
factors by a number of mechanisms. Our understanding
of DNA methylation has advanced rapidly in recent years
with the identification of an increasingly large number of
novel proteins involved in this process. These include
methylcytosine-binding proteins as well as additional
members of the DNA methyltransferase family. The cre-
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ation of mice with targeted deletions in a number of genes
involved in DNA methylation has further elucidated the
functions of many of these proteins. The characterization
of complexes that contain proteins known to be involved
in DNA methylation has led to the identification of addi-
tional proteins, especially those involved in histone
deacetylation, indicating that DNA methylation and his-
tone deacetylation very likely act in a synergistic fashion
to regulate gene transcription. Finally, the implication of
DNA methylation in tumorigenesis and the realization
that some congenital diseases are caused by deficiency of
proteins involved in DNA methylation has confirmed the
importance of this process in regulating gene expression.
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Methylcytosine, CG dinucleotides and CpG islands
First discovered over 50 years ago in calf thymus [1],
methylation of DNA occurs mostly at the 5 position of cy-
tosine in higher eukaryotic cells (fig. 1). Although approx-
imately 4% of cytosines present in the genome are methy-
lated, all of the methylcytosine residues are found in the
context of 5¢-cytosine guanine-3¢ (CG) dinucleotides, of
which ~70–80% contain methylcytosine (for early re-
views see [2, 3]). Of great functional significance is the fact
that methylcytosines occur in a nonrandom distribution
throughout the genome [4]. When DNA is analyzed for CG
dinucleotide pairs, regions with higher proportions of CG
sequences than would be expected by chance are found to
exist [5]. Such CG-rich regions, referred to as CpG islands,
constitute between 1 and 2% of the total genome, but ac-
count for most of the nonmethylated CG dinucleotides. The
remaining CG dinucleotides occur outside of CpG islands
and are largely methylated. CpG islands have been identi-
fied in organisms with large genomes such as vertebrates
and some higher plants [6]. A connection between CpG is-
lands and gene structure first became apparent with the
finding that regions of the genome accessible to nucleases,
and therefore likely to be involved in active gene transcrip-
tion, contained hypomethylated DNA [4]. Further studies
on CG dinucleotide distribution found that their frequency
was higher at the 5¢ end compared to the 3¢ end of 15 ran-
domly selected genes [5].* Corresponding author.
CpG islands were subsequently identified at the 5¢ end of
a number of individual genes, including murine MHC
class I and II genes, as well as dihydrofolate reductase
and chicken a2 type I collagen [7]. Similar results were
obtained when restriction fragments were generated with
HpaII cleavage, an enzyme whose target site contains an
unmethylated CG dinucleotide. These fragments were
found to be relatively unmethylated and consisted of se-
quences with high C + G content (65%), compared with
bulk DNA (40%) [8]. The increased frequency of CG
pairs in CpG islands is reflected in the CG/GC ratio of ap-
proximately 1, a fivefold increase compared with 0.2 for
bulk DNA [9]. The low CG/GC ratio in bulk DNA re-
flects the tendancy for methylcytosine to undergo deami-
nation to thymine, which is repaired less efficiently by
thymine-DNA glycosylase than the corresponding deam-
ination of unmethylated cytosine to uracil, which is cor-
rected by uracil-DNA glycoslyase [10].
An early indication of a relationship between CpG islands
and the presence of genes came from restriction enzyme
analysis using methylation-sensitive CG restriction en-
zymes [11]. Using the enzyme SacII, 3 out of 4 CpG is-
lands were found to be associated with active gene ex-
pression. As chromatin structure can also act as a marker
for active genes, CpG island chromatin was compared
with that of bulk chromatin and found to have signifi-
cantly reduced amounts of histone H1, higher levels of
histone H3 and H4 acetylation, and regions within CpG
islands free of nucleosomes [12]. All these features are
characteristic of transcriptionally active chromatin and
further support the notion that CpG islands colocalize
with the promoter region of active genes. This was con-
firmed in a comprehensive analysis of CpG islands in the
European Molecular Biology Laboratory (EMBL) data-
base [13]. Examination of 375 genes and 58 pseudogenes
revealed 240 CpG islands, virtually all of which covered
part of at least one exon. More than half the genes con-
tained CpG islands, and all housekeeping genes and
widely expressed genes were found to have a CpG island
covering the transcription start site [13]. It should be
noted, however, that CpG islands do not occur exclusively
within the 5¢ region of genes but have also been identified
downstream of transcription initiation sites within the
transcribed region of a number of genes [14].
As noted above, most of the CG dinucleotides outside of
CpG islands are methylated, and the large majority of
these are found in transposable elements such as retro-
transposons, L1 elements, Alu sequences and endoge-
nous retroviruses, as well as juxtacentromeric satellite se-
quences. DNA methylation is believed to play a critical
role in the suppression of parasitic and other repeat se-
quences (reviewed in [15–17]).
The DNA methyltransferases
DNA methyltransferase 1. Cloned in 1988, DNA methyl-
transferase 1 (Dnmt1) remained the only known mam-
malian DNA methyltransferase for 10 years [18]. Dnmt1,
like bacterial methyltransferases, catalyzes the transfer of
a methyl group from S-adenosylmethionine to the 5¢ po-
sition on cytosine (fig. 2). The protein, 1620 amino acids
long, consists of a C-terminal domain containing the cat-
alytic site, and is more similar to bacterial DNA C5-spe-
cific restriction methyltransferases than the other more
recently identified mammalian DNA methyltransferases
[18]. The N-terminal region consists of multiple domains,
including a nuclear localization signal, a zinc-finger
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Figure 1. Mechanisms by which DNA methylation inhibits gene transcription. (A) Hypomethylation of CpG dinucleotides within a pro-
moter region allows transcription factors to bind and transcription to occur. (B) Methylation of CpGs inhibits transcription factor binding
and therefore gene transcription. (C) The presence of methylcytosine-binding proteins (MBPs) bound to CpGs within a promoter region
also blocks access of transcription factors to their binding sites. (D) MBPs bound to CpGs in the promoter region form complexes with
histone deacetylases and corepressors, leading to histone deacetylation, chromatin condensation and a transcriptionally inactive chromatin
structure.
DNA binding domain [18] and a domain for targeting
Dnmt1 to the replication fork during S phase [19]. DNA
binding may occur through a number of domains, includ-
ing the zinc binding domain, the catalytic domain and the
nuclear localization sequence containing the domain
[20]. However, it has also been reported that the target
recognition domain for hemimethylated CG is located
within the N terminus between amino acids 122 and 
417 [21].
Our understanding of the mechanism by which methyl-
transferase enzymes methylate cytosine has been greatly
advanced by the crystalographic analysis of the bacterial
methyltransferase HhaI [22], which showed that the tar-
get cytosine is everted from the DNA helix and inserted
into the active site of the enzyme. All known DNA cyto-
sine-5-transferases contain 10 sequence motifs, with 6
being very strongly conserved [23].
Dnmt1 is believed to primarily mediate maintenance
methyltransferase activity during S phase because of its
5–30-fold preference for hemimethylated DNA as com-
pared with nonmethylated DNA [24]. However, there is
some evidence to suggest that Dnmt1 might also have de
novo methyltransferase capabilities. First, an in vitro
study of de novo methyltransferase activity found that all
identifiable de novo activity in embryo lysates resided
with Dnmt1 [24]. Second, forced overexpression of
Dnmt1 led to de novo methylation in both myocytes [25]
and fibroblasts [26]. Whether Dnmt1 mediates de novo
methylation under normal biological conditions remains
to be determined, although human immunodeficiency
virus (HIV) infection was shown to result in upregulation
of Dnmt1 expression and activity, resulting in de novo
methylation of the interferon g (IFNg) promoter and sup-
pression of the IFNg gene [27].
Differential usage of alternative exons at the 5¢ end of the
gene gives rise to different isoforms in various tissues. In
particular, the pattern of Dnmt1 expression in oocytes is
quite different from that of other tissues. The oocyte-spe-
cific 5¢ exon is associated with a Dnmt1 protein that is
truncated at the N terminus and sequestered in the cyto-
plasm during the later stages of oocyte growth [28]. Tar-
geted deletion of the oocyte-specific promoter and first
exon led to a loss of normal genomic imprinting [29]. By
contrast, a spermatocyte-specific 5¢ exon was shown to
interfere with translation and therefore synthesis of
Dnmt1 protein [28], although an identical transcript has
also been identified in differentiated skeletal muscle my-
otubes and shown to be translated despite the presence of
a number of out-of-frame upstream ATGs [30].
Targeted homozygous Dnmt1 deletion leads to embry-
onic lethality prior to mid-gestation [31]. Although em-
bryonic stem (ES) cells with the targeted mutation grow
normally despite markedly demethylated genomes, they
undergo apoptosis when induced to differentiate [31].
However, despite Dnmt1 deletion, the ES cells retain the
capacity for de novo methylation. Dnmt1 also appears to
be necessary for genomic imprinting [32] and X chromo-
some inactivation [33].
Three recent studies have confirmed or at least supported
the tendency for apoptosis to occur in differentiated cells
that are completely deficient in Dnmt1. First, Cre-medi-
ated deletion of Dnmt1 in cultured fibroblasts lead to
DNA hypomethylation followed by p53-dependent apop-
tosis [34]. Second, Cre-mediated deletion at the CD4+
CD8+ double-positive thymocyte stage resulted in a
markedly reduced number of cell cycles by stimulated
naive T cells, followed by growth arrest and cell death
[35]. Finally, conditional Dnmt1 deletion in mitotic cen-
tral nervous system (CNS) precursor cells in utero re-
sulted in rapid elimination of mutated cells within 3
weeks of postnatal life [36].
Dnmt1 has now been shown to associate with many dif-
ferent proteins, including proliferating cell nuclear anti-
gen (PCNA) [37], the transcription elongation factor
E2F1, the retinoblastoma tumor suppressor protein Rb
and the histone deacetylase HDAC1 [38]. It has also been
shown to associate with a complex containing HDAC2,
DMAP1, a recently identified DNMT1-binding corepres-
sor protein, and TSG101, another corepressor [39].
De novo methylation and the methyltransferases Dnmt3a
and Dnmt3b. The realization that additional DNA
methyltransferases must exist arose from the observation
that although Dnmt1 knockout embryos die prior to the
eight-somite stage in association with widespread
demethylation, Dnmt1-deficient embryonic stem cells
are viable and maintain a low level of DNA methylation
as well as cytosine methyltransferase activity. Further-
more, transfected proviral DNA that becomes integrated
undergoes de novo methylation at the same rate as wild-
type cells [40]. These findings suggested the existence of
one or more de novo methyltransferases.
By screening the dbEST database with the bacterial re-
striction methyltransferase M.XorI, a second methyl-
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Figure 2. Formation of 5-methylcytosine. A DNA methyltrans-
ferase enzyme catalyzes the transfer of a methyl group (CH3) from
S-adenosylmethionine (SAM) to (deoxy)cytosine, producing 5-(de-
oxy)methylcytosine and S-adenosylhomocystine (SAH).
transferase, Dnmt2, was identified [41]. However, al-
though Dnmt2 contains all 10 of the sequence motifs
characteristic of DNA (cytosine-5)-methyltransferases, it
lacks the N-terminal regulatory domain of other eukary-
otic methyltransferases and has no detectable methyl-
transferase activity in vitro [42]. Furthermore, embryonic
stem cells deficient for Dnmt2 display normal methyla-
tion of endogenous viral sequences as well as de novo
methylation of newly integrated retroviral DNA [42].
Given that it binds strongly to DNA through a specific
target-recognizing motif, Dnmt2 may identify specific
sequences within the genome for some as yet unknown
biological function.
With additional EST database screening using full length
bacterial type II cytosine-5 methyltransferase sequences
as queries, two additional DNA methyltransferases,
Dnmt3a and Dnmt3b, were discovered [43]. Both en-
zymes are capable of methylating unmethylated and
hemimethylated DNA equally in vitro [43]. Structurally,
both of the Dnmt3 proteins contain a catalytic domain at
the C terminal, an adjacent cysteine-rich domain and a
variable domain at the N terminal. The catalytic domain
of both Dnmt3a and Dnmt3b contains all of the invariant
amino acids in the five highly conserved domains I, IV,
VI, IX and X [44]. The cysteine-rich domain is homolo-
gous to a similar domain in the X-linked ATRX gene of
the SNF2/SW1 family that is known to mediate its asso-
ciation with the histone deacetylase HDAC1 [45].
Although Dnmt1 possesses de novo methylation activity
in vitro, targeted deletion of either of the Dnmt3 genes
has confirmed the essential requirement of Dnmt3a or
Dnmt3b for de novo methylation in vivo [46]. Methyla-
tion of a recombinant retrovirus transfected into ES cells
required either Dnmt3a or Dnmt3b, but not both, indicat-
ing redundancy of de novo methylation function. Al-
though Dnmt3a knockout mice appeared normal at birth,
most became runted and died at about 4 weeks of age.
Dnmt3b embryos, however, died in utero from multiple
developmental defects. Endogenous C-type retroviral
DNA was normally methylated in Dnmt3a knockout mice
and slightly undermethylated in Dnmt3b knockout mice.
However, double-knockout mice demonstrated marked
hypomethylation of these endogenous retroviral se-
quences. Examination of the role of Dnmt3a and Dnmt3b
in the methylation of imprinted genes produced mixed re-
sults. Whereas the methylation status of the region 2 in-
tronic CpG island of Igf2r and the 5¢ upstream region of
H19 was unchanged in double-knockout ES cells, almost
complete demethylation of DMR2, another region of the
Igf2r gene, occurred in the same cells. Finally, a unique
role for Dnmt3b in the methylation of juxtacentromeric
minor satellite repeats was revealed in ES cells from the
Dnmt3b knockout, which had substantially hypomethy-
lated satellite repeats. This is consistent with the associa-
tion of Dnmt3b mutations and the congenital disease ICF
(see below). Although the studies on de novo methylation
of transfected retroviruses suggested redundancy of func-
tion of Dnmt3a and Dnmt3b, their unique patterns of tis-
sue expression in the embryo suggest that they have sep-
arate functions.
The demonstration of physiological de novo methylation
activity has largely been confined to the postimplantation
embryo and primordial germ cells of midgestation em-
bryos. With the exception of de novo methylation of the
CD8 coreceptor gene [47], there is no evidence to date
that de novo methylation plays a significant role in the
normal regulation of gene expression apart from embry-
onic tissues. Similarly, little is known regarding the func-
tions of the de novo methyltransferases in nonembryonic
tissues. However, expression of Dnmt3a and 3b has been
shown in various adult tissues [43, 48], and it is reason-
able to suggest that there may be de novo methyltrans-
ferase activity occuring in these tissues. We have identi-
fied upregulation of both Dnmt3a and Dnmt3b during the
early stages of T cell activation [authors’ unpublished
data]. Dnmt3a has recently been shown to associate with
RP58, a DNA-binding protein with transcriptional re-
pressor activity, and also with HDAC1 via its ATRX-
homologous domain. Furthermore, Dnmt3a was shown
to act as a corepressor with RP58, independent of its
methyltransferase activity [45].
DNA demethylation. Very little is known about the
process of genomic demethylation. That it occurs at all is
clearly demonstrated in the developing embryo, in which
a wave of demethylation following fertilization leads to
an almost complete conversion of methylcytosines to cy-
tosines [49, 50]. However, demethylation of DNA in adult
tissue is poorly characterized and with few exceptions has
not yet been clearly demonstrated in normal cells. The
generally accepted view is that demethylation occurs dur-
ing development when gene expression patterns in so-
matic cells are being laid down and genes become acti-
vated in a cell-type specific fashion. Excluding embry-
onic studies, most evidence for demethylation events
comes from analysis of transfected genes [51]. In addi-
tion, a global loss of methylcytosines occur in many tu-
mors as well as with ageing, as will be discussed later.
Demethylation of genomic DNA can occur in two ways.
First, passive demethylation occurs only in the context of
DNA replication. This is thought to be the primary mech-
anism of demethylation mediated by cytosine analogs
such as 5-azacytidine. It has been suggested that certain
DNA-binding factors may block cytosine methylation
that normally occurs during S phase [52].
The second mechanism occurs independent of DNA syn-
thesis, and involves the action of demethylases. The first
evidence for demethylase activity occurred with the
demonstration of demethylation activity in nuclear ex-
tracts of chicken embroyos [53]. Demethylation was
shown to occur through nucleotide excision repair of 5-
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methyldeoxycytidine. Subesequently, the protein respon-
sible for this activity was identified as 5-methylcytosine
DNA glycosylase (5-MCDG) [54] and found to require
RNA for its demethylating function [55]. Both enzyme
and RNA appear to exist in a larger complex that also
contains an RNA helicase and the G/T mismatch DNA
glycosylase [56]. The RNA may play a role in recognition
of methylated CG dinucleotides. When overexpressed in
human embryonic kidney cells, 5-MCDG has recently
been shown to specifically demethylate a stably inte-
grated ecdysone-retinoic acid responsive enhancer-pro-
moter [57]. Whether the function of 5-MCDG is primar-
ily that of a demethylase rather than a DNA repair en-
zyme remains to be elucidated.
One of the methylcytosine binding proteins, MBD4, has
also been shown to act as a demethylase with similar 5-
methylcytosine glycosylase activity [58]. Although an-
other methylcytosine-binding protein, MDB2, has been
shown to have demethylase activity, catalyzing the direct
reaction of the 5-methylcytosine moiety with water to
form cytosine and methanol [59], this has not been con-
firmed by others [60, 61] (see below for further discus-
sion of MBD2 and MBD4).
Relationship between DNA methylation
and gene expression
Tissue-specific gene methylation. A role for DNA methy-
lation in gene regulation was first proposed in the 1970s
[62, 63], and supporting evidence has accumulated over
the intervening years. Most of the early data was correla-
tive. Methylation of the rabbit b globin gene [64] and sub-
sequently other genes was noted to occur in a tissue-spe-
cific pattern, consistent with a role of methylation in tis-
sue-specific gene regulation. Further studies on the
tissue-specific expression of the chicken b globin [65]
and ovalbumin [66] genes as well as the human b globin
locus [67] demonstrated a positive correlation between
hypomethylation and gene expression in different tissues.
Cytosine analogs. Evidence has also come from the use
of DNA methyltransferase inhibitors such as the cytosine
analogs 5-azacytidine and 5-aza-2¢-deoxycytidine. The
earliest experiments involved treatment of mouse embry-
onic cells with 5-azacytidine, which gave rise to differen-
tiated phenotypes, including muscle cells, adipocytes and
chondrocytes [68]. These changes were subsequently
shown to be associated with DNA hypomethylation [69].
DNA substituted with 5-azacytidine covalently binds
DNA methyltransferase enzymes, leading to loss of ac-
tivity and DNA hypomethylation [70]. However, the cy-
totoxicity of these cytosine analogs may be independent
of their ability to cause DNA hypomethylation, as mice
partially deficient in DNA methyltransferase activity are
actually more resistant to the cytotoxic effects of 5-aza-
2¢-deoxycytidine [71]. Since the original experiments
with mouse embryonic cells, there have been numerous
reports of the induction of new cellular phenotypes in re-
sponse to treatment with cytosine analogs (reviewed in
[72]), although the known inhibitory effects of these
agents on cell division may have contributed to the ob-
served phenotypic changes [73, 74]. Induction of specific
gene expression by 5-azacytidine treatment was first re-
ported for the HGPRT gene located on the inactive X
chromosome [75]. This report also lead to an understand-
ing of the fundamental role that DNA methylation plays
in X chromosome inactivation. Upregulation of perhaps
many hundreds if not thousands of genes secondary to cy-
tosine analog treatment have since been reported (early
experiments are reviewed in [72]).
Genomic imprinting and X chromosome inactivation. In
vivo evidence for the involvement of DNA methylation in
gene regulation is found in the biological phenomena of
genomic imprinting and X chromosome inactivation. In
both, gene silencing is strongly associated with hyperme-
thylation of CpG islands within the promoter region of si-
lenced genes. Genomic imprinting is a process whereby
only one of the two parental alleles is expressed, whereas
the other gene is imprinted or silenced by DNA methyla-
tion (reviewed in [76–80]). Imprinted genes are germline
derived and inherited from either the maternal or paternal
gamete. About 45 imprinted genes have been identified in
the mouse, and ~88% have CpG islands [81]. By gener-
ating uniparental mouse embryonic fibroblasts and treat-
ing with DNA methylation inhibitors, it was possible to
induce expression of some but not all imprinted genes
[82]. However, the mechanism of imprinting is quite
complex and, in addition to CpG island methylation, in-
volves insulator or boundary elements, repressor proteins
such as CTCF and antisense transcripts (reviewed in [80,
83–86]). Nevertheless, DNA methylation appears to play
a critical role in the regulation of these processes as well.
The functional significance of genomic imprinting is un-
clear, but, as hypothesized in the ‘conflict theory’, may be
a genetic mechanism to balance the in utero growth re-
quirements of the developing fetus versus the health of
the mother [87–90].
X chromosome inactivation is a related methylation-de-
pendent phenomenon and consists of the transcriptional
silencing of one of the two X chromosomes in mam-
malian females. This is to ensure equivalent levels of
gene expression from the sex chromosomes in both males
and females, i.e. gene dosage compensation (reviewed in
[91–94]).
Transfection of differentially methylated genes (patch
methylation). Although it has been possible to pharmaco-
logically demethylate CG dinucleotides in DNA of cul-
tured cells, pharmacological methylation of specific un-
methylated CGs in vivo has not been feasible to date. One
experimental approach used to overcome this problem is
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the methylation of genes in vitro using bacterial methyl-
transferases and their transfection back into cells. An
early example is the in vitro methylation of the hamster
adenine phosphoribosyltransferase (aprt) gene at all
CCGG sites with HpaII methylase and its subsequent
transfection into murine L cells. Compared with cells
transfected with the nonmethylated gene, methylation in-
hibited aprt expression [95]. Similarly, in vitro methyla-
tion of the human g globin gene in its 5¢ region but not
elsewhere inhibited its expression following transfection
into mouse L cells [96]. Many similar experiments have
now been performed, demonstrating a suppressive effect
of DNA methylation on transfected genes. Recently, a
more physiological approach was achieved by creating a
transgenic mouse containing a 120-bp island element
(IE) sequence that consisted of two Sp1 sites from the
hamster aprt CpG island [97]. This sequence was able to
protect itself and also CG dinucleotides up to 150 bp
away from de novo methylation. By creating a loxP-
flanked version of this sequence, it was possible to gen-
erate Cre-mediated deletion at either the preimplantation
stage before the normal wave of de novo methylation had
taken place, or later in the adult mouse. With the IE
placed within a reporter gene, it was possible to show that
Cre-mediated deletion prior to the wave of de novo
methylation lead to persistent methylation and sup-
pressed expression of the reporter construct, whereas
deletion in the adult mouse did not lead to further methy-
lation [97].
Mechanisms by which DNA methylation
regulates gene expression
Direct inhibition of transcription factor binding. DNA
methylation may suppress gene transcription in two gen-
eral ways (fig. 1). First, methylated CG dinucleotides
may directly interfere with the binding of transcription
factors to their recognition sequences, presumably by
protruding into the major DNA groove. The movement of
RNA polymerase along the gene does not seem to be af-
fected by methylation, because coding regions down-
stream of the promoter usually contain CG dinucleotides
that are mostly methylated. This suggests that for methy-
lated CG dinucleotides to directly inhibit transcription,
they must lie in or near promoter sites or other cis-acting
regulatory elements. This has been demonstrated for the
binding of AP-2 to its recognition sequence within the
promoter site of the proencephalin gene. Methylation of a
CCGG site within the AP-2 binding sequence inhibited
binding of AP-2 and is thought to explain the inhibition
of expression of a proenkephalin-CAT fusion gene
methylated at CCGG sites [98]. Similar inhibition has
been demonstrated for the binding of ATF/CREB to the
cyclic AMP (cAMP)-responsive element [99] and c-Myc
to its regulatory element [100]. However, although Sp1
binding has also been shown to be inhibited by DNA
methylation [101], the presence of methylated CG within
its recognition sequence did not prevent its binding to a
synthetic oligonucleotide containing this methylated
recognition sequence [102]. In addition to this direct in-
terference by methylated cytosines with the binding of
transcripton factors to DNA, methylcytosine binding pro-
teins can also prevent the binding of transcription factors
to their promoter sequences [103].
Methylcytosine-binding proteins, histone deacetylase
complexes and indirect inhibition of transcription factor
binding. Second, regions of methylated DNA adjacent to
the promoter sites of genes may recruit methylcytosine-
binding proteins (see table 1) that in turn associate with
large protein complexes containing corepressors and his-
tone deacetylases. The binding of these complexes to
DNA leads to a change in the chromatin structure from an
active to an inactive form. The best-characterized methyl-
cytosine-binding protein is MeCP2, identified by its abil-
ity to bind to DNA containing as little as a single methy-
lated CG dinucleotide [104]. MeCP2 contains a methyl-
CG binding region within an 85-amino acid domain near
the N terminus [105] as well as a transcriptional-repres-
sion domain between amino acids 221 and 249 [106].
MeCP2 is concentrated in juxtacentromeric heterochro-
matin that contains a large fraction of all genomic
methylcytosine [104, 107]. Murine MeCP2 associates
with the Sin3A histone deacetylase complex, consisting
of at least seven proteins including the transcriptional re-
pressor Sin3A and histone deacetylases HDAC1 and
HDAC2 [108], thus linking DNA methylation with his-
tone deacetylation. Histone deacetylation suppresses
gene expression by removing acetyl groups from his-
tones, which in turn leads to more compact chromatin
that is transcriptionally inactive (reviewed in [109]). A
similar association occurs between homologous proteins
in Xenopus laevis oocytes [110]. However, transcriptional
repression by MeCP2 may also occur independent of hi-
stone deacetylases [103], suggesting that MeCP2 may di-
rectly compete with transcription factors, thereby pre-
venting gene expression. Because of the abundance of
methylated CG dinucleotides within the genome, MeCP2
may act as a global transcriptional repressor [106].
Two additional histone deacetylase complexes have been
identified. These include MeCP1 [60, 111], which con-
tains the methyl-CpG binding domain protein 2 (MBD2),
the histone deacetylases HDAC1 and HDAC2, and the
retinoblastoma protein-binding proteins RbAp46 and
RbAp48 (also present in the Sin3A histone deacetylase
complex). The latter were previously shown to copurify
with histone deacetylases and may mediate core-histone
binding of the histone deacetylase complex. The second
histone deacetylase complex is the Mi-2 (or NuRD) com-
plex that contains at least seven proteins, including Mi-2,
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a protein believed to have chromatin remodeling activity,
HDAC1, HDAC2, RbAp46, RbAp48 and also the methyl-
cytosine-binding protein MBD3 [112]. Interestingly,
MBD2 has been found in association with both Sin3A
[113] and also the Mi2/NuRD complex [112], and is likely
to play a role in gene repression mediated by both Sin3A
and the Mi2/NuRD histone deacetylase complexes.
Dnmt1 has also been identified in a complex that contains
both Mbd2 and Mbd3, binds to hemimethylated DNA
and is located at the replication focus during late S phase
[114]. The genes for both Mbd2 and Mbd3 have very re-
cently undergone targeted deletion [115]. Mbd3 knock-
out mice die during early embryogenesis, whereas Mbd2
knockout mice appear to be largely normal except for de-
fective maternal behavior.
In addition to MBD2 and MBD3, the MBD family of
methylcytosine-binding proteins includes two further
members, MBD1 and MBD4 [116, 117]. MBD1 contains
a transcriptional repression domain, binds to methylcyto-
sine-containing DNA and suppresses gene transcription
at a distance from its binding site. Its ability to suppress
transcription is overcome by the histone deacetylase in-
hibitor trichostatin A, indicating the involvement of
deacetylases in gene suppression mediated by MBD1.
However, MBD1 does not appear to associate with
HDAC1 as do MeCP2, MBD2 and MBD3, suggesting it
may differ in its mode of action [118]. Unlike the other
MBD family members, MBD4 does not suppress gene
transcription but functions as a G/T mismatch glycosy-
lase activity as well as having 5-methylcytosine DNA
glycosylase activity [119].
CMLS, Cell. Mol. Life Sci. Vol. 59, 2002 Review Article 247
Table 1. DNA Methyltransferases and Methylcytosine-Binding Proteins.
Protein Function Binding Site Deficiency/Disease States
1. DNA Methyltransferases
Dnmt1 Maintenance of DNA methylation pattern DNA replication foci Embryo-lethal in muring knockout.
during S phase. De novo methylation SLE associated with reduced levels.
in vitro. Methylation independent in-
hibition of gene transcription in vitro
Dnmt2 Unknown. No detectable DNA unknown Normal phenotype of knockout ES
methyltransferase activity in vitro cells. No known human deficiency.
Dnmt3a De novo methylation in vivo (lost in pericentromeric DNA Death at about 4 weeks in murine
Dnmt3a/3b double-knockout embryo) and elsewhere in the knockout. No known human
and in vitro. Methylation-independent nucleus deficiency. Possible involvement in 
inhibition of gene transcription in vitro promoter hypermethylation in tumors.
Dnmt3b De novo methlation in vivo (lost in pericentromeric DNA Embryo-lethal in murine knockout.
Dnmt3a/3b double-knockout embryo). and elsewhere in the nucleus ICF syndrome associated with
Methylation of pericentromeric mutations in DNMT3b in humans.
DNA satellite repeats. Methylation- Possible involvement in promoter
independent inhibition of gene hypermethylation in tumors.
transcription in vitro
2. Methylcytosine-Binding-Proteins
MeCP2 Suppression of gene expression in vitro methylated DNA; Peri- Neurological abnormalities in
and in vivo, both alone and in conjunction centromeric satellite DNA various murine knockout models.
with Sin3A histone deacetylase complexes. especially rich in MeCP2; Rett syndrome and X-linked
May act as global suppressor of gene may require as many as mental retardation associated with
expression 10 CpGs for bindung mutations in MeCP2 in human
MBD1 Suppression of gene expression. methylated DNA, especially No published murine knockout.
Probably associated with as yet pericentromeric satellite DNA; No known human deficiency.
unidentified histone deacetylases. may require only a single
CpG dinucleotide for binding
MBD2 Suppression of gene expression. Methylated DNA, especially Abnormal maternal behavior in
Associated with MeCP1, Sin3A pericentromeric satellite DNA murine knockout. No known
and Mi2/NuRD histone deacetylase human deficiency.
complexes. One report of demethylase
activity, but not reproducible by others.
MBD3 Suppression of gene expression. nuclear foci, but apparently Embryo-lethal in murine knockout.
Associated with Mi2/NuRD not methylated DNA No known human deficiency.
histone deacetylase complex.
MBD4 G/T mismatch and 5-methycytosine methylated DNA, especially No published murine knockout. No 
DNA glycosylase activity. Possibly pericentromeric satellite DNA known human deficiency. Possible 
involved in DNA demethylation. tumor suppressor gene, mutated in 
some colorectal carcinomas.
DNA methylation and the regulation
of immune system genes
INFg and other cytokine genes. Increasing evidence has
emerged in recent years for a prominent role of epigenetic
regulation, including DNA methylation, of immune sys-
tem genes. Much effort has focused on the regulation of
cytokine gene expression in the context of T-helper-cell
subset generation and in particular the IFNg gene (re-
viewed in [120]). An early indication of the importance of
DNA methylation in IFNg regulation was the finding that
CG dinucleotides close to or within the gene were rela-
tively hypomethylated in T cells relative to other tissues
and cell lines [121]. Further, levels of IFNg expression
correlated inversely with the degree of DNA methylation
in a number of T cell lines [121]. Expression of IFNg was
subsequently confirmed to correlate with the presence or
absence of methylation of a CG dinucleotide within a
TATA proximal regulatory element of the IFNg promoter
region, with almost complete methylation of this site oc-
curing in nonexpressing Th2 clones but partial or com-
plete hypomethylation in Th1 clones, which express this
gene. In addition, treatment of human Th2 clones with 5-
azacytidine induced IFNg production [122]. Methylation
analysis of three CG sites within the 5¢-flanking region
and first intron of the IFNg gene revealed that thymo-
cytes, neonatal T cells and naive adult T cells had an al-
most completely methylated IFNg gene. This was in con-
trast to the relatively hypomethylated state of the IFNg
gene of T cell lines that expressed IFNg at high levels
[123]. A regulatory element within the IFNg promoter de-
termining tissue-specific expression contains a CG dinu-
cleotide that is selectively methylated in Th2 cells and
other cell types that do not express IFNg [124]. In addi-
tion, methylation of this CG dinucleotide reduced bind-
ing of the transcription factors CREB, ATF-2 and Jun
[124]. After TCR ligation, human naive CD4 T cells se-
creted IFNg and coincidentally partially demethylated a
CG dinucleotide with the TATA proximal regulatory ele-
ment [125]. Interestingly, both the upregulation of IFNg
secretion and the associated CG demethylation were in-
hibited by prostaglandin E and interleukin (IL)-4. In-
creased IFNg gene methylation and the associated de-
creased expression have also been observed in CD4 T
cells from tumor-bearing mice in response to treatment
with phosphatidyl serine [126].
Analogous to T-cell-activation-related decreases in IFNg
promoter methylation, demethylation of CG dinu-
cleotides within the IL-4 promoter have also been shown
to occur concomitantly with T cell activation under Th2-
but not Th1-polarizing conditions [127]. Comparison of
D5 and D10, Th1 and Th2 clones respectively, also re-
vealed differential demethylation of the IL-4 locus in D10
cells associated with Il-4 secretion [127]. Treating naive
T cells with 5-aza-2-deoxycytidine under nonpolarizing
conditions led to significantly increased numbers of IL-
4-positive cells (as well as increased IFNg-positive cells)
in a cell-cycle-dependent fashion [128]. Both the IL-4
and IL-5 loci were found to be differentially demethy-
lated in a Th2 T cell clone as compared with a Th1 clone.
Detailed kinetic analysis demonstrated IL-4 locus de-
methylation between days 4 and 7 following Th2 priming
[128]. In fact, coordinate chromatin remodeling appears
to occur within the whole IL-4/IL-5/IL-13 gene cluster
with Th2 polarization of naive T cells, although the role
of DNA methylation in this process remains to be deter-
mined [127, 129].
Finally, demethylation of CG sites within the IL-3 pro-
moter occurs in activated CD8+ T cell clones, with most
of the demethylation occuring at a specific CG dinu-
cleotide 164 bp upstream of the transcriptional start 
site [130].
CD4 and CD8 coreceptor genes. Regulation of CD4 and
CD8 coreceptor gene expression has also been associated
with CG methylation. Early work from our lab demon-
strated the induction of CD4 expression in CD8+ T cells
treated with the DNA methyltransferase inhibitor 5-aza-
cytidine [131]. Analysis of CD8 gene methylation status
in thymocytes revealed progressive demethylation during
the transition from CD4–CD8– single-positive to
CD4+CD8+ double-positive thymocytes [132]. Similar
demethylation was observed in the CD4 gene locus dur-
ing thymocyte maturation from CD4–CD8– double-neg-
ative cells through CD4+CD8+ double-positive, CD4+
single-positive thymocytes and finally CD4+ peripheral
T cells [133]. CD8 gene expression in a CD4+CD8+ T
cell derivative of a CD4+CD8– T cell line was associated
with demethylation at a number of sites within the CD8
gene [134]. Examination of the CD8b gene 5¢ regulatory
region has also identified CG dinucleotides that are dif-
ferentially demethylated in CD8b-expressing thymocytes
and peripheral T cells [135]. Recently, it was noted that
continued CD8 expression is required for survival of pe-
ripheral CD8+ T cells. In the absence of engagement of
both the T cell receptor and CD8 coreceptor, CD8a
downregulation occurs by de novo methylation of the
CD8a gene and subsequent apoptosis through a Fas-Fas
ligand interaction [47]. An earlier study also reported the
occurrence of de novo methylation in association with
CD8a downregulation in a T cell hybridoma [136].
Major histocompatibility complex genes. A role for DNA
methylation in the regulation of MHC gene expression is
more controversial, with evidence both for and against. In
the case of the class II trans-activator (CIITA) gene, there
is good evidence that CG methylation within its IFNg-in-
ducible promoter IV is important in suppressing IFNg-in-
ducible CIITA expression and therefore also the expres-
sion of major histocompatibility (MHC) class II genes in
normal trophoblastic cells, which downregulate MHC ex-
pression in general to avoid immune recognition [137,
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138]. As CIITA is also involved in the regulation of MHC
class I genes, it is possible that methylation-induced sup-
pression of CIITA expression may also lead to MHC class
I gene downregulation in some tissues. As for the MHC
class II genes themselves, there is some evidence that, at
least in the case of the HLA-DR a gene, extensive methy-
lation did not prevent transcription [139], and analysis of
various melanoma cell lines treated with IFNg [140] as
well as other mononuclear cell lines [141] demonstrated
no correlation between human leukocyte antigen (HLA)-
DR gene expression and levels of methylation. In fact,
early analysis of melanoma and other cell lines unexpect-
edly found an positive correlation between HLA-DR a
gene methylation levels and gene expression [142, 143].
Most MHC class I genes are associated with hypomethy-
lated CpG islands [144].
Although methylation of murine class I genes has been
described, this has also been in the context of increased
rather than reduced expression of the methylated gene
[145, 146]. Similarly, whereas MHC class I expression is
suppressed in trophoblastic tissue, there is no evidence
that any of the MHC class I genes are methylated [147].
Further research on the issue of DNA methylation and
MHC gene regulation would help clarify these issues,
particularly as much of the research is not of recent 
origin.
T- and B-cell-receptor gene rearrangement. Another area
of epigenetic immune gene regulation that has recently
attracted considerable attention is the control of recombi-
nation events during the somatic rearrangement of T- and
B-cell-receptor gene segments (reviewed in [148]). An
early indication for a possible role of DNA methylation in
antigen receptor regulation was the finding that the J
chain gene was heavily methylated in B cell lines not ex-
pressing the J chain, whereas cell lines expressing the
protein contained hypomethylated J chain genes [149].
Further work on B cells found that the degree of heavy-
chain gene methylation correlated inversely with level of
expression. In addition, all immunoglobulin loci were
found to become increasingly demethylated with increas-
ing B cell maturity [150].
Subsequent studies on the T cell receptor (TCR) demon-
strated that the rearranged TCR-b-chain gene was highly
unmethylated in mature peripheral blood T cells com-
pared with nonexpressing B cells and monocytes [151].
Further research by the same group demonstrated that the
TCR-b-chain region was hypomethylated in either CD4+
or CD8+ single-positive murine thymocytes as compared
with the less mature CD4–CD8– subset, whereas the
same region was heavily methylated in macrophages
[152]. Analysis of TCR methylation changes using
methylation-sensitive enzymes has confirmed demethy-
lation of the TCR-b locus during CD4–CD8– to
CD4+CD8+ thymocyte differentiation [153]. In addition,
studies on the locus control region (LCR) for the TCR-
a/d locus using germline deletions of two DNase I-hy-
persensitivity site clusters within the LCR suggest that
these elements may mediate directed demethylation of a
localized region within the LCR itself [154].
Deletion of the TCR-b enhancer leads to persistence of
methylation within Db–Jb clusters which normally be-
come demethylated in developing thymocytes [155]. Fi-
nally, another mouse model containing deletion of the
germline transcriptional promoter PDb1 also demon-
strates DNA hypermethylation in the Db1–Jb1 region
and reduced Db1 rearrangement compared with normal
mice [156]. In this case, methylation of a specific CG din-
ucleotide within one of the recombination signal se-
quences completely blocked the cleavage which would
normally occur during VDJ recombination.
DNA methylation and disease states
Inherited disorders of methylation. With the increasing
numbers of proteins known to be involved in the methy-
lation process, it is not surprising that a number of genetic
disorders have now been linked to congenital deficiencies
of some of these proteins. Characteristic developmental
abnormalities are a prominent feature of most of these
disorders.
The ICF syndrome (immunodeficiency, centromere in-
stability and facial anomalies) is a rare autosomal reces-
sive disorder characterized by facial abnormalities, men-
tal retardation and immunoglobulin deficiencies [157].
Lymphocytes from ICF patients demonstrate cytogenetic
abnormalities, primarily localized to the juxtacen-
tromeric regions of chromosomes 1, 9 and 16. Somewhat
similar changes are seen when normal cells are treated
with the demethylating agent 5-azacytidine [158]. These
chromosomal regions are rich in tracts of classical satel-
lites 2 and 3, which are usually heavily methylated, but
are markedly hypomethylated in the ICF syndrome [159].
This disorder is now known to be associated with muta-
tions in Dnmt3b [46, 160] and is consistent with
Dnmt3b’s known role in methylating juxtacentromeric
satellite repeats [46]. None of the mutations leads to com-
plete absence of the enzyme, a condition that is lethal in
embryonic dnmt3b-deficient mice [46].
Another inherited condition, Rett syndrome, is one of the
most common causes of female mental retardation [161].
Affected girls usually have no phenotype until 6–18
months of age, when they gradually lose speech and pur-
poseful hand use and develop microencephaly, seizures,
ataxia, episodes of hyperventilation and stereotypic hand
movements. Mutations in the methylcytosine-binding
protein MeCP2 are now known to occur in individuals
with Rett syndrome [162]. The strongly neurodevelop-
mental nature of this disorder is consistent with the nor-
mally high levels of MeCP2 expression found in the
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brain. Recently, MeCP2 knockout mice have been gener-
ated by targeted deletion [163, 164]. These mice develop
severe neurological symptoms by about 6 weeks old, and
heterozygous females also demonstrate abnormal behav-
ior after several months. It is postulated that MeCP2 is in-
volved in maintaining the stability of brain function
rather than brain development [163].
A third condition associated with dysregulation of methy-
lation is the ATR-X syndrome, characterized by severe,
X-linked mental retardation, facial dysmorphism, uroge-
nital abnormalities and alpha-thalassemia [165]. ATRX is
a member of the SNF2 family, whose members all have
similar adenosine triphosphate (ATP)ase and helicase do-
mains. ATRX is localized to pericentromeric heterochro-
matin during interphase and mitosis. Mutations in the
ATRX gene have been shown to be associated with alter-
ations in the methylation patterns of a number of highly
repeated sequences, including hypomethylation of ribo-
somal DNA arrays, hypermethylation of the Y-specific re-
peat DYZ2 and other subtle changes in subtelomeric re-
peats [166].
Defects in the imprinting process occurs in a number of
developmental disorders, including Prader-Willi syn-
drome; the related disorder, Angelman’s syndrome; and
Beckwith-Wiedemann syndrome [167]. Prader-Willi
syndrome is characterized by mild-to-moderate mental
retardation associated with neonatal hypotonia, hypogo-
nadism, short stature secondary to reduced growth hor-
mone secretion, facial dysmorphia and hyperphagia
[168]. The condition results from lack of transcripts ex-
pressed from the paternal copy of the imprinted chromo-
somal region 15q11–q13 [169]. Angelman syndrome is a
similar disorder in which a deletion has occurred in the
same region of chromosome 15 but on the maternal chro-
mosome [169]. Beckwith-Wiedemann syndrome is an
overgrowth condition associated with various abnormali-
ties of the chromosome 11p15 region, a region that is
known to be subject to genomic imprinting. One result is
the overexpression of insulin-like growth factor 2 (IGF2)
that may in part be responsible for the overgrowth 
[170, 171].
Finally, a number disorders arise from the expansion of
trinucleotide repeats within genes. Fragile X syndrome, a
common form of inherited mental retardation, is one such
disorder and is associated with marked expansion of a
CCG triplet within the 5¢-untranslated region of the
FMR1 gene on the X chromosome [172]. Such expansion
occurs in germ cells and gives rise to ‘anticipation’ in suc-
ceeding families. The silencing of the FMR1 gene ap-
pears to occur via methylation of the expanded trinu-
cleotide repeat as well as a CpG island within the pro-
moter region of the gene itself, with associated histone
deacetylation leading to absence of FMR1 protein [173].
Methylation and autoimmune disease. There have been
few studies into the role of abnormal DNA methylation in
diseases apart from cancer. Systemic lupus erythemato-
sus (SLE) is an autoimmune disease that primarily effects
women and is characterized by increased antibody pro-
duction and abnormalities in T cell function. The hypoth-
esis that T cell DNA hypomethylation might be a factor in
the etiopathogenesis of SLE originally arose from the ob-
servation in our lab that CD4+ T cells treated with 5-aza-
cytidine become autoreactive and respond to autologous
macrophages without the need for antigen [174]. In addi-
tion, 5-azacytidine-treated CD4+ T cells induce autolo-
gous B cell differentiation in the absence of any require-
ment for exogenous antigen [175]. The autoreactivity is
due in part to the overexpression of the adhesion mole-
cule LFA-1 (CD11a/CD18), since causing LFA-1 overex-
pression by transfection causes an identical autoreactivity
[176]. Because of the known relationship between hy-
dralazine and procainamide and the development of SLE,
these drugs were investigated for their effects on DNA
methylation, and found to inhibit DNA methylation as
well as induce LFA-1 overexpression and autoreactivity
in CD4+ T cells [177].
These observations led to the question whether DNA hy-
pomethylation might be associated with human SLE and
other autoimmune diseases. Supporting evidence arose
from studies of SLE and rheumatoid arthritis patients
which demonstrated hypomethylated DNA in T cells
from these patients as compared with normal controls
[178]. These findings were confirmed by another group
[179]. Further evidence supporting an etiologic role for
T cell DNA hypomethylation in autoimmunity came
from studies in which stimulated murine CD4+ T cells
were treated with DNA methylation inhibitors, including
5-azacytidine, procainamide and hydralazine, then in-
jected into syngeneic mice. The recipients developed a
lupus-like disease with anti-DNA antibodies, as well as
a liver disease resembling primary biliary cirrhosis
[180]. More recent work has shown that the same region
flanking the CD11a promoter is demethylated in the
drug treated T cells as in T cells from patients with active
lupus [B.C. Richardson et al., unpublished results]. The
DNA hypomethylation in lupus T cells appears to result
from decreased extracellular signal-related kinase
(ERK) pathway signaling, leading to decreased Dnmt1
and Dnmt3a expression [B.C. Richardson et al., unpub-
lished results].
Methylation and cancer. Both global hypomethylation
and regional hypermethylation have been recognized as
characteristic of many tumors [181]. Hypomethylation
has been suggested to lead to activation of protoonco-
genes such as H-RAS and C-MYC, as well as members
of the MAGE gene family (reviewed in [182]). However,
the last few years has seen a remarkable explosion in re-
search concerning the association of CpG island hyper-
methylation with tumorigenesis. This interest has arisen
from the observation that CpG islands within the promot-
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ers of many genes are found to be hypermethylated and
suppressed in a variety of tumors [183, 184].
Although the association between CpG island hyperme-
thylation and cancer has not been clearly shown to be
causal, examination of affected genes is highly suggestive
of a such a relationship. Causality predicts that hyperme-
thylation of CpG islands within the 5¢ region of genes
with various growth suppressing functions leads to sup-
pressed gene expression with resultant dysregulated cell
growth. Genes with hypermethylated CpG islands so far
include tumor suppressor genes such as the RB1 gene in
retinoblastomas and other tumors [185, 186] and the von
Hippel Lindau (VHL) gene in renal carcinoma [187];
genes involved in apoptosis such as the death-associated
protein (DAP) in lung cancer [188]; and DNA-repair
genes such as MLH1 in colorectal tumors [189, 190].
Methylation changes for a specific gene occur quite fre-
quently for a given cancer type [184]. Both CpG island
hypermethylation and mutation changes in a specific
gene can be found in a particular tumor type, further sup-
porting the argument for a causal role of DNA methyla-
tion in tumorigenesis [191]. As discussed below, methy-
lation changes may occur in normal tissue and precede
the development of cancer [192, 193].
Interestingly and very relevant for diagnostics, abnormal
promoter methylation occurs in the same location within
an affected gene for different individuals and regardless
of the tumor type [194]. The fact that the phenomenon of
CpG island hypermethylation is relatively common in a
wide variety of tumors suggests that for some reason, a
directed methylation event targeted to CpG islands is oc-
curring, whose normal biological equivalent is unclear at
this time.
Methylation and ageing. Age-related changes in the lev-
els of DNA methylation within promoter regions have the
potential to mediate abnormal gene expression. Such
changes might contribute to tissue senescence as well as
the increased incidence of malignancy that occurs with
age [195]. Early studies demonstrated that global levels
of DNA methylation tend to decrease with age
[196–199], although there are exceptions [200]. Such
changes may represent demethylation primarily of repet-
itive DNA sequences [197, 201, 202]. Age-related
demethylation of endogenous retroviruses has also been
demonstrated and may be associated with the increase in
expression of these sequences that occurs with age [203].
Our group examined total methylcytosine content of 
human T cells and found that although an increase ac-
companies the differentiation of thymocytes into ma-
ture T cells, total methylcytosine content decreases with
age [204].
Individual genes undergo tissue-specific methylation
changes with age, such that demethylation may occur in
one tissue and not another [205]. For example, the c-Myc
gene demethylated with age in murine spleen while dis-
playing increased methylation at some CG dinucleotides
in murine liver [206], although the methylation changes
did not consistently correlate with transcript levels [207].
Other genes have also been found to display age-related
changes in methylation [205]; however, promoter in-
volvement and changes in gene expression have not been
clearly defined.
Because of their potential to influence the level of gene
expression, CpG islands within the promoters of genes
which are normally hypomethylated have recently been
analyzed for evidence of age-associated increases in
methylation (reviewed in [208, 209]). This work arose
from the observation that gene inactivation in many tu-
mors occurs as a result of hypermethylation of CG islands
within their promoters, especially those of tumor sup-
pressor genes (reviewed in [210]). The estrogen receptor
(ER) gene was first identified as being associated with
age-related CpG island hypemethylation in a subpopula-
tion of normal human colonic mucosa cells [192]. Further
studies by the same group demonstrated diminished or
absent ER expression in virtually all colorectal tumors
examined, and introduction of an exogenous unmethy-
lated ER gene caused marked growth suppression, sug-
gesting that ER CpG island hypermethylation may be an
earlier event in the development of colorectal tumors
[192]. Further analysis of CpG island methylation in
colonic tissue revealed that 19/30 (63%) of CpG islands
examined had undergone progressive methylation in an
age-dependent fashion [193]. Aside from the increased
risk of tumor development that is associated with ageing,
it remains to be seen whether hypermethylation of CpG
islands is a factor in other aspects of age-related gene
dysfunction.
Our group has studied the effects of a heterozygous dele-
tion mutation of Dnmt1 (Dnmt1+/–) with respect to im-
mune senescence and autoimmunity [211]. As we had al-
ready shown that inhibiting T cell DNA methylation leads
to autoimmunity, we hypothesized that Dnmt1+/– mice
would develop immune senescence and autoimmune dis-
ease more rapidly than their normal littermates. Surpris-
ingly, Dnmt1+/– mice showed a reduced degree of age-
related lymphocytic infiltration in the liver and salivary
glands, as well as lower titers of anti-DNA antibodies,
compared with their normal littermates. Analysis of T
cells from Dnmt1+/– mice revealed that the CD44 high-
memory subset developed more slowly, IL-2 secretion
was maintained in old age and T cell proliferative re-
sponses increased rather than decreased with age. Analy-
sis of lymphocyte DNA total methylcytosine content
demonstrated that although DNA from young Dnmt1+/–
mice was hypomethylated, the methylcytosine content
paradoxically increased with age compared with normal
littermates, whose lymphocyte methylcytosine content
declined with age. Interestingly, when transcript levels
for methylcytosine-binding proteins were analyzed in
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brain tissue, we found that although MeCP2 showed an
age-related decline in normal littermates, levels in
Dnmt1+/– mice remained unchanged.
Conclusion
Over the past few years there has been enormous progress
in our understanding of the mechanisms of DNA methy-
lation and the role that this process plays in normal cellu-
lar function as well as in certain congenital diseases, tu-
mor development, aging and autoimmune disease. It is
likely that the next few years will lead to further insights
into this process, with the expectation that such knowl-
edge will allow the development of therapeutic modali-
ties able to manipulate methylcytosine levels in DNA or
interfere with the normal downstream effects of differen-
tially methylated DNA. Certainly, the newly identified
DNA methyltransferases and methylcytosine-binding
proteins will be targets for pharmocological or genetic in-
hibition, especially in the development of anticancer
agents. However, further research will be required to un-
derstand how abnormalities of the methylation machin-
ery lead to disease states and what components of this
machinery will be appropriate targets for therapeutic in-
tervention.
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